Custom service
Biosimilar Immunogenicity Assessment
Compare immunogenicity profiles of biosimilar vs reference products
Biosimilar Immunogenicity Assessment supports programmes that compare immunogenicity profiles of biosimilar vs reference products. In a typical engagement we plan the comparative ADA assay design route first, confirm compatibility with head-to-head sample testing, and release comparative immunogenicity report on a 10–16 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep comparative ADA assay design as the primary option and hold head-to-head sample testing in reserve, so that scale-up never depends on an unproven step.
Biosimilar filing support
Post-change comparability checks
Originator clinical data generation
Samples requiring containment or licensing we do not hold (BSL-3, radioactive)
Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.
Service Highlights
- Comparative ADA assay design as the default route, with head-to-head sample testing held as a proven fallback
- Similarity statistics worked into the design where the application requires it
- Results are reported with detection limits and method validation status, so you know exactly what the number means
- Analytical confirmation of every intermediate before the final release
- Orthogonal methods are used by default — one measurement is an observation, two are data
- Comparative immunogenicity report delivered with a complete conjugation or synthesis certificate
How the work runs
Sample intake & plan
Samples are logged with chain of custody and the test matrix for Biosimilar Immunogenicity Assessment is confirmed.
Method selection
Analytical methods — comparative ADA assay design, head-to-head sample testing — are chosen and their validation status documented.
Measurement
Testing is executed with system-suitability checks and orthogonal confirmation where required.
Data review
Chromatograms and spectra are reviewed by a second analyst before any result is issued.
Reporting
Comparative immunogenicity report is issued with detection limits and interpretation notes.
Follow-up support
We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.
Specifications & timeline
- Turnaround
- 10–16 weeks
- Typical scale
- µg – g sample scale
- Chemistry options
- comparative ADA assay design; head-to-head sample testing; similarity statistics
- Deliverable
- Comparative immunogenicity report
- QC package
- Method report, raw data, validated result with detection limits
- Shipping
- Blue ice or ambient by material; chain-of-custody on receipt
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.